More R&D investment and globalization is daunting challenge for Korea

Published: 2010-08-10 06:59:00

Updated: 2010-08-10 06:59:00

The Korean government’s new drug pricing policy and crackdown on rebates is ultimately designed to encourage domestic drug manufacturers to invest in R&D for the development of new drugs.

According to government data, 14,900 medical entities were registered for health insurance coverage as of ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK